ea0021p199 | Endocrine tumours and neoplasia | SFEBES2009
Wysota Barbara
, Horne Stephanie
, Smyth Angharad
, Anwar Aresh
, Sankar Sailesh
, Weickert Martin
Cinacalcet increases sensitivity of the calcium sensing-receptor, currently licenced for treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease. It decreases parathyroid hormone, calcium and phosphorus levels. There is no clinical data for the use of Cinacalcet in pregnancy. Hyperparathyroidism is rare during pregnancy, mainly presenting early, when surgery is safely performed. Here we report a patient presenting with a MEN1-associated p...